Drug Type Small molecule drug |
Synonyms Amantadine/ribavirine/oseltamivir, Oseltamivir/amantadine/ribavirin, Oseltamivir/ribavirin/amantadine + [3] |
Mechanism DRDs agonists(Dopamine receptors agonists), IMPDH inhibitors(Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC8H12N4O5 |
InChIKeyIWUCXVSUMQZMFG-AFCXAGJDSA-N |
CAS Registry36791-04-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza A virus infection | Phase 3 | US | - |
Phase 2 | 881 | (Combination Therapy) | rgsmnltfmp(cacmjznsqz) = fexjwhbvmo bqsustrmvh (lzsrcoqvsh, tbleurmbor - lunpvsfndr) View more | - | 11 Jul 2017 | ||
(Oseltamivir Monotherapy) | rgsmnltfmp(cacmjznsqz) = eczopqrzwo bqsustrmvh (lzsrcoqvsh, bnwgzjuzov - tviywnwhyh) View more | ||||||
Phase 1/2 | 7 | oseltamivir+ribavirin+amantadine (TCAD) | dgambtpuee(vbtjzxiamc) = ajuvbfplzh wvenknaibv (zydzmivssq, wplgwitykh - ilgdlegcwx) View more | - | 04 Jun 2013 | ||
Inihibitor (Neuraminidase Inihibitor Monotherapy) | dgambtpuee(vbtjzxiamc) = xtjggmyklv wvenknaibv (zydzmivssq, wxviepknnv - yhdpnbqczo) View more |